Venus gets market authorisation from Swiss drug authority

Tags: Companies
Pharma major Venus Remedies has secured its first marketing authorisation in Switzerland from Swiss drug authority 'Swissmedic' for its oncology drug 'Gemcitabine'.

The marketing approval for Gemcitabine will help the company further strengthen its oncology portfolio and improve its presence in this space, Venus Remedies said in a statement here today.

The Panchkula-based company plans to launch the drug early next quarter and the product will be launched in Switzerland by Swiss Pharma GmbH, with which Venus has a marketing tie-up, it said.

"The launch of this product will add to the company's top line and bottom line in the coming quarters," it said.

Venus Remedies has already received more than 20 marketing approvals for Gemcitabine injection from various countries. The product is being sold in the UK, Poland and Germany.

Gemcitabine is an anti-cancer drug used for the treatment of a variety of cancerous conditions, including the cancer of the lungs, pancreas, bladder and breast.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Ordinances are being used as an easy route to push tough political agendas

    Article 123 of the Constitution of India remains a landmark feature of the country’s most important judicial document.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

Uncertainty in climate sensitivity

Climate sensitivity is a metric used to characterise the response ...

Zehra Naqvi

A thrilling journey

Amrita Chowdhury could well be India’s Jeffery Archer. Edge-of-the-seat thriller ...

Bubbles Sabharwal

Time to gift ourselves some good cheer

The other day, my labrador Cesar asked me, “You do ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture